Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
OBJECTIVE
To report the effect of superficial keratectomy combined with subconjunctival bevacizumab injection in 2 cases of corneal neovascularization (NV).


METHODS
An interventional case series was undertaken on 2 patients with corneal NV: 1 due to sclerokeratitis secondary to rheumatoid arthritis and the other due to Terrien marginal degeneration. Both patients underwent superficial keratectomy combined with subconjunctival bevacizumab injection (2.5 mg/0.1 mL).


RESULTS
Corneal NV regressed with the surgical removal and showed no signs of recurrence after 3 months of follow-up. Both patients reported dramatic subjective improvement in their vision within 1-2 weeks. Best corrected visual acuity improved in 1 patient.


CONCLUSIONS
The combination of superficial keratectomy with subconjunctival injection of bevacizumab may offer a new strategy for the treatment of superficial corneal NV.
Qian
Cynthia Xin-ya
CX
Department of Ophthalmology, University of Montreal, Montreal, Quebec, Canada. xin-ya.qian@mail.mcgill.ca
Bahar
Irit
I
Levinger
Eliya
E
Rootman
David
D
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva; D003315:Cornea / Q000473:pathology / Q000601:surgery*; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D013508:Ophthalmologic Surgical Procedures; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab